HAVCR2 and glioma: Clinical trials of anti-B7-H3 (NCT02475213) and anti-Tim-3 (NCT02817633) are carrying on, and our study showed the fatty acid catabolic metabolism-related gene risk signature might be a possible metabolic marker of the immunotherapy for gliomas.